Episode 423: Understanding Infections and MS with Dr. Robert Fox
Release Date: 10/06/2025
RealTalk MS
In 1988, there were just 42 Walk MS events, raising approximately $4 million. In 2025, there were 170 events across the country that raised over $30 million. As the largest private funder of MS research in the world, the National MS Society relies on funds raised at events like Walk MS to continue supporting the work that brings us closer to cures. This week, Brigitte Delaney, an amazing fundraiser and captain of the Many Sisters Walk MS team, shares her story, talks about the origin of the Many Sisters team, and offers her recipe for successful fundraising. We're also sharing...
info_outlineRealTalk MS
175 MS activists are heading to Washington, D.C. next week for the National MS Society’s Public Policy Conference. Their mission: to bring the concerns of the MS community directly to lawmakers on Capitol Hill. When it comes to the legislative support for healthcare and medical research, it's no secret that these are unusual times. Joining me to brief us on the National MS Society's ongoing advocacy efforts and give us a sneak peek at the specific legislative issues we'll be taking to Capitol Hill is the National MS Society's Vice President of Advocacy, Steffany Stern. We'll...
info_outlineRealTalk MS
It’s MS Awareness Week, and this year we’re diving into a theme that hits home for millions: Unseen MS. Multiple sclerosis is a master of disguise; it can be entirely invisible to the naked eye while remaining profoundly life-altering for the person living it. In this episode, we’re exploring the spectrum of the MS experience through two distinct, yet deeply connected stories. First, you'll hear from RealTalk MS team member Kristine Werner Ozug. Kristine shares what it’s like to navigate a world that doesn’t always see her struggle, and how her "mostly invisible"...
info_outlineRealTalk MS
You know them by their trade names such as Ozempic, Wegovy, Mounjaro, and Zepbound. This class of medications is known as GLP-1 receptor agonists. And while they are best known for managing diabetes and promoting weight loss, researchers are finding that these drugs are also effective in a broad range of other health conditions. So, what about MS? My guest this week is Dr. Ellen Mowry, the principal investigator of a clinical trial to determine whether a GLP-1 drug can reduce brain inflammation and provide neuroprotection in people living with progressive MS. We're sharing details...
info_outlineRealTalk MS
Welcome back to the third and final part of our coverage of the 2026 ACTRIMS Forum. This week's episode bridges the gap between groundbreaking clinical research and the nuanced reality of living with MS every day. First, we'll dive into the "before" and "after" of a diagnosis, starting with Dr. Helen Tremlett’s insights into the MS prodrome—those subtle, early signs that appear years before typical MS symptoms. We'll also talk with Dr. Tremlett about how other health conditions can predict long-term outcomes in sometimes surprising ways. Dr. Ilana Katz Sand shares her latest...
info_outlineRealTalk MS
Welcome back to Part Two of our coverage of the 2026 ACTRIMS Forum. This week, we shift our focus to emerging therapies and clinical insights that are re-shaping the future of MS care. From the latest information on stem cell transplantation to evolving treatment strategies to the labels used to describe MS, we’re breaking down the complex science into the conversations that matter most to the MS community. Joining me to discuss one of the most significant presentations from the 2026 ACTRIMS Forum is Dr. Jeffrey Cohen, who opened the event with the Kenneth P. Johnson Memorial...
info_outlineRealTalk MS
Last week, over 1,400 scientists and clinicians gathered in San Diego, California, at the 2026 Americas Committee for Treatment and Research in Multiple Sclerosis annual meeting, better known as the ACTRIMS Forum. This week, in Part One of our coverage, you'll hear from three of the experts who presented their research at the ACTRIMS Forum. Dr. Manuel Friese, a clinician-scientist at the Institute of Neuroimmunology and Multiple Sclerosis at the University Medical Center Hamburg-Eppendorf in Hamburg, Germany, where he serves as the Director of the Center for Molecular...
info_outlineRealTalk MS
This past December, the FDA issued a Complete Response Letter to drug manufacturer Sanofi in response to Sanofi's application seeking approval for Tolebrutinib, the first in a new category of investigational disease-modifying therapies to undergo FDA review. A Complete Response Letter is an official letter from the FDA to a drug manufacturer stating that the agency can't approve a new medicine in its current form. It's not an outright "no" that kills a project; it's more like a "not yet." However, this Complete Response Letter raised some issues which, at first...
info_outlineRealTalk MS
The first coordinated global research strategy to prevent MS has been announced. This week, Dr. Bruce Bebo, the National MS Society's Executive Vice President and Chief Research & Medical Affairs Officer, joins me to explain what MS prevention looks like and how experts plan to achieve this remarkable goal. We'll also tell you who won the 2025 Barancik Prize for Innovation in MS Research, and we'll explain how their groundbreaking research impacts MS care. We're sharing the details of a newly announced partnership designed to reduce delays in getting an MS diagnosis and expand...
info_outlineRealTalk MS
One of the more confusing aspects of MS is that it can present differently from one person to the next. A research team at University College London may have uncovered a reason for that when they identified two new, and quite different, subtypes of MS. Joining me to walk us through this discovery and to explain how it may impact MS clinical care is the study's principal investigator, Dr. Arman Eshaghi. We're also sharing study results that may explain how the Epstein-Barr Virus triggers MS in some individuals. We'll tell you about the free online fitness and wellness...
info_outlineFrom the earliest days of the COVID-19 pandemic, people living with MS have been justifiably concerned about how a COVID-19 infection might impact their MS. As the new "Stratus" strain of COVID-19 is currently surging in the United States, research is providing answers we didn't have five years ago.

Dr. Robert Fox, the Managing Director of the NARCOMS Patient Registry, joins me to discuss how COVID-19 infections and other infections impact people with MS.
As ECTRIMS, the world's largest MS research conference, approached, many attendees anticipated the FDA's decision on whether to approve Tolebrutinib, the first in a new category of disease-modifying therapies. Instead, the FDA has requested additional time for its review. We'll fill you in on the FDA's new target action date, and explain why there's strong interest in this particular disease-modifying therapy.
We know there's a specific gene that increases the risk of someone developing MS. But have you ever wondered where that gene came from, or why it exists at all? At ECTRIMS, Professor Lars Fugger took us on a journey 5,000 years into the past to explain its origin. When I spoke with him, Professor Fugger also explained how events from ancient history are still affecting the risk of developing MS today. You won't want to miss this compelling conversation!
At ECTRIMS, I also caught up with Jason Tardio, the President, and Dr. Andreas Muehler, the Chief Medical Officer, from Immunic Therapeutics. We talked about how their investigative drug, vidofludimus calcium, could potentially benefit people with MS by combating inflammation, protecting the nervous system, and offering antiviral benefits.
We have a lot to talk about! Are you ready for RealTalk MS??!
This Week: Infections and MS, and more from ECTRIMS 2025! :22
FDA extends its review of Tolebrutinib 1:42
From ECTRIMS: Professor Lars Fugger discusses the origin of the gene that increases an individual's risk of developing MS 4:11
From ECTRIMS: Jason Tardio, President, and Dr. Andreas Muehler, Chief Medical Officer, at Immunic Therapeutics, discuss how vidofludimus calcium could potentially benefit people with MS 11:22
Dr. Robert Fox discusses what the research reveals about how COVID-19 infections and other infections impact people living with MS 16:34
Share this episode 32:00
Next week's episode 32:19
SHARE THIS EPISODE OF REALTALK MS
Just copy this link & paste it into your text or email: https://realtalkms.com/423
ADD YOUR VOICE TO THE CONVERSATION
I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!
Email: jon@realtalkms.com
Phone: (310) 526-2283
And don't forget to join us in the RealTalk MS Facebook group!
LINKS
If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com
PARTICIPATE: Take the Shaping Tomorrow Together Survey
https://s.alchemer.com/s3/Perspectives-on-MS
REGISTER: Attend the virtual Shaping Tomorrow Together meeting with the FDA
https://nmss.quorum.us/event/25463
SIGN UP: Become an MS Activist
https://nationalmssociety.org/advocacy
JOIN: The RealTalk MS Facebook Group
https://facebook.com/groups/realtalkms
DOWNLOAD: The RealTalk MS App for iOS Devices
https://itunes.apple.com/us/app/realtalk-ms/id1436917200
DOWNLOAD: The RealTalk MS App for Android Devices
https://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk
REVIEW: Give RealTalk MS a rating and review
http://www.realtalkms.com/review
Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.
RealTalk MS Episode 423
Guests: Professor Lars Fugger, Jason Tardio, Dr. Andreas Meuhler, and Dr. Robert Fox